Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous cancer vaccine - Vaccinogen

Next Previous
Drug Profile

Autologous cancer vaccine - Vaccinogen

Alternative Names: Active specific immunotherapy - Vaccinogen; ASI - Vaccinogen; Autologous tumour cell vaccine - Vaccinogen; Colon cancer vaccine - Intracel; OncoVAX

Latest Information Update: 29 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intracel Corporation
  • Developer Intracel Corporation; National Cancer Institute (USA); Vaccinogen
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer
  • No development reported Malignant melanoma; Renal cancer
  • Discontinued Ovarian cancer

Most Recent Events

  • 18 Aug 2017 Vaccinogen's autologous cancer vaccine is at phase II development stage for Colorectal cancer (Combination therapy, Adjuvant therapy) in Netherlands and USA (Intradermal) (Vaccinogen website, August 2017)
  • 18 Aug 2017 No recent reports on development identified - Phase-III for Colorectal cancer (Adjuvant therapy) in Netherlands (Intradermal)
  • 18 Aug 2017 Vaccinogen plans a clinical trial for Colorectal cancer (Combination therapy) (Vaccinogen website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top